Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,821Revenue (TTM) $M276Net Margin (%)-13.7Altman Z-Score6.2
Enterprise Value $M1,757EPS (TTM) $-1.0Operating Margin %-11.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-13.7Higher ROA y-yN
Price/Book7.710-y EBITDA Growth Rate %--Quick Ratio4.7Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %--Current Ratio5.4Lower Leverage y-yN
Price/Free Cash Flow195y-y EBITDA Growth Rate %-193.0ROA % (ttm)-9.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-17.2Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M39.9ROIC % (ttm)-19.3Gross Margin Increase y-yN

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PCRX is held by these investors:



PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Scibetta James SPresident 2017-01-17Sell20,000$38.5317.31view
STACK DAVID MCEO and Chairman 2017-01-17Sell15,000$38.4117.68view
STACK DAVID MCEO and Chairman 2016-11-15Sell15,000$37.2821.24view
Scibetta James SPresident 2016-11-15Sell20,000$36.523.84view
STACK DAVID MCEO and Chairman 2016-08-15Sell15,000$45.32-0.26view
Scibetta James SPresident 2016-08-15Sell25,000$45.21-0.02view
Riker Lauren BullaroVice President, Finance 2016-06-07Sell938$47.66-5.16view
Williams Kristen MarieCAO and General Counsel 2016-06-06Sell600$47.2-4.24view
Kronenfeld Mark A.Director 2016-06-06Sell900$46.95-3.73view
Brege LauraDirector 2016-06-06Sell1,000$46.95-3.73view

Press Releases about PCRX :

Quarterly/Annual Reports about PCRX:

News about PCRX:

Articles On GuruFocus.com
MonoSol Rx Appoints James S. Scibetta to Board of Directors Apr 11 2017 
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference Apr 03 2017 
4 Biotech Stocks to Watch Mar 22 2017 
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide Mar 16 2017 
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption Mar 14 2017 
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 13 2017 
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Conver Mar 08 2017 
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Con Mar 06 2017 
Baron Funds Comments on PaciraPharmaceuticals Jan 18 2017 
Investing in Earlier Stage Small Cap Growth Companies - Baron Discovery Fund Jan 18 2017 

More From Other Websites
Can Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse? Apr 19 2017
Can Drugmakers Cure the Opioid Crisis? Apr 18 2017
Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : April 17, 2017 Apr 17 2017
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US :... Apr 13 2017
Pacira Focuses on Lead Candidate Exparel's Label Expansion Apr 12 2017
MonoSol Rx Appoints James S. Scibetta to Board of Directors Apr 11 2017
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference Apr 03 2017
Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound? Apr 03 2017
Anesthesia Can't Save This Biotech From Feeling Pain: Analyst Mar 23 2017
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide Mar 16 2017
Why Pacira Pharmaceuticals Stock Is Already Up 56% This Year Mar 15 2017
Pacira Pharmaceuticals stock rises 2% on positive late-stage trial for opioid-reducing pain... Mar 14 2017
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption... Mar 14 2017
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Mar 13 2017
Is Pacira Pharmaceuticals' Balance Sheet Safe? Mar 09 2017
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375%... Mar 07 2017
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of... Mar 06 2017
ETFs with exposure to Pacira Pharmaceuticals, Inc. : March 6, 2017 Mar 06 2017
Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy Mar 06 2017
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential Mar 03 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)